Sarepta Therapeutics Cash Flow Statement
NASDAQ: SRPTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Sarepta Therapeutics free cash flow
In fiscal 2025, Sarepta Therapeutics generated -$205.5 million of operating cash flow and spent $102.0 million on capital expenditures. That left free cash flow of -$307.5 million, a free-cash-flow margin of -14.0% of revenue. Sarepta Therapeutics returned $25.0 million to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
Sarepta Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -713.41M | 235.24M | -535.98M | -703.49M | -418.78M | -554.13M | -715.08M | -361.92M | -50.69M | -267.26M |
| Net Income growth (YoY) | -403.27% | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 44.52M | 37.72M | 44.40M | 41.86M | 38.02M | 26.91M | 24.50M | 12.24M | 8.09M | 5.61M |
| Stock-Based Compensation | 123.40M | 184.30M | 182.51M | 233.02M | 113.94M | 108.07M | 78.60M | 50.13M | 30.46M | 29.96M |
| Change in Working Capital | -105.07M | -638.67M | -418.43M | -229.60M | -121.46M | 512.06M | -189.86M | -198.05M | -110.39M | -23.08M |
| Operating Cash Flow | -205.48M | -205.79M | -500.99M | -325.35M | -443.17M | 107.47M | -456.46M | -388.66M | -232.00M | -245.82M |
| Capital Expenditures | -101.97M | -136.96M | -76.11M | -30.82M | -38.49M | -82.20M | -59.63M | -61.16M | -12.00M | -5.34M |
| Investing Cash Flow | 69.64M | 755.56M | -165.80M | -1.05B | 495.41M | -121.72M | 286.73M | -370.49M | -178.81M | -90.19M |
| Share Repurchases | -25.01M | 0 | 0 | — | — | — | — | — | — | — |
| Debt Issued | — | — | — | 0 | 0 | 291.15M | 245.63M | — | 30.00M | — |
| Debt Repaid | — | 0 | 0 | -550.00M | 0 | 0 | — | -1.26M | -109.00K | -2.60M |
| Financing Cash Flow | -168.34M | 124.81M | 125.00M | 232.51M | 561.57M | 682.32M | 642.55M | 530.15M | 888.08M | 378.13M |
| Net Change in Cash | -304.18M | 674.58M | -541.79M | -1.14B | 613.81M | 668.07M | 472.82M | -229.00M | 477.27M | 42.12M |
| Free Cash Flow | -307.45M | -342.74M | -577.10M | -356.17M | -481.66M | 25.26M | -516.09M | -449.82M | -244.00M | -251.16M |
This table shows 10 annual periods of Sarepta Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SRPT's reporting calendar. What is a cash flow statement?